{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:22:23Z","timestamp":1788492143145,"version":"build-2803163510"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.neuropharm.2020.108053","type":"journal-article","created":{"date-parts":[[2020,3,15]],"date-time":"2020-03-15T10:21:26Z","timestamp":1584267686000},"page":"108053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"special_numbering":"C","title":["\u03b17 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: Update on animal and clinical studies and strategies for the future"],"prefix":"10.1016","volume":"170","author":[{"suffix":"Jr.","given":"Alvin V.","family":"Terry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Callahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.neuropharm.2020.108053_bib1","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/0269881117746903","article-title":"Assessing the acute effects of CDP-choline on sensory gating in schizophrenia: a pilot study","volume":"32","author":"Aidelbaum","year":"2018","journal-title":"J. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.neuropharm.2020.108053_bib2","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/npp.2008.232","article-title":"Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia","volume":"34","author":"Barak","year":"2009","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.neuropharm.2020.108053_bib3","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.cortex.2012.05.022","article-title":"Dorsolateral prefrontal contributions to human working memory","volume":"49","author":"Barbey","year":"2013","journal-title":"Cortex"},{"key":"10.1016\/j.neuropharm.2020.108053_bib4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.pnpbp.2016.06.013","article-title":"Task-related fMRI responses to a nicotinic acetylcholine receptor partial agonist in schizophrenia: a randomized trial","volume":"71","author":"Barch","year":"2016","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"17","key":"10.1016\/j.neuropharm.2020.108053_bib5","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.1523\/JNEUROSCI.18-17-06871.1998","article-title":"Nicotinic receptor-induced apoptotic cell death of hippocampal progenitor cells","volume":"18","author":"Berger","year":"1998","journal-title":"J. Neurosci."},{"issue":"8","key":"10.1016\/j.neuropharm.2020.108053_bib6","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.bcp.2007.07.011","article-title":"Allosteric modulation of nicotinic acetylcholine receptors","volume":"74","author":"Bertrand","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108053_bib7","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.bcp.2017.12.008","article-title":"The wonderland of neuronal nicotinic acetylcholine receptors","volume":"151","author":"Bertrand","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"39","key":"10.1016\/j.neuropharm.2020.108053_bib8","doi-asserted-by":"crossref","first-page":"10578","DOI":"10.1523\/JNEUROSCI.2444-07.2007","article-title":"Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1\/2 and CREB phosphorylation pathways","volume":"27","author":"Bitner","year":"2007","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.108053_bib9","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1124\/jpet.110.167213","article-title":"In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease","volume":"334","author":"Bitner","year":"2010","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108053_bib10","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1124\/jpet.106.118976","article-title":"The novel alpha7 nicotinic acetylcholine receptor agonist N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-(7-(2-methoxyphenyl)-1-benzofuran)-2-carboxamide improves working and recognition memory in rodents","volume":"321","author":"Boess","year":"2007","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108053_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-012-2933-4","article-title":"Pharmacological and behavioral profile of N-((3R)-1-azabicyclo(2.2.2)oct-3-yl)-6-chinolincarboxamide (EVP-5141), a novel \u03b17 nicotinic acetylcholine receptor agonist\/serotonin 5-HT3 receptor antagonist","volume":"227","author":"Boess","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108053_bib12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.expneurol.2014.09.015","article-title":"The \u03b17 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions","volume":"263","author":"Bordia","year":"2015","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2020.108053_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0159996","article-title":"The novel, nicotinic alpha7 receptor partial agonist, BMS-933043, improves cognition and sensory processing in preclinical models of schizophrenia","volume":"11","author":"Bristow","year":"2016","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108053_bib14","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1124\/jpet.108.145292","article-title":"Desensitization of nicotinic acetylcholine receptors as a strategy for drug development","volume":"328","author":"Buccafusco","year":"2009","journal-title":"J Pharmacol Exp Ther. Feb"},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108053_bib15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/schbul\/sbi020","article-title":"A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia","volume":"31","author":"Buchanan","year":"2005","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.neuropharm.2020.108053_bib16","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/JCP.0000000000000720","article-title":"A randomized clinical trial of oxytocin or galantamine for the treatment of negative symptoms and cognitive impairments in people with schizophrenia","volume":"37","author":"Buchanan","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2020.108053_bib17","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejphar.2014.07.030","article-title":"Decreasing nicotinic receptor activity and the spatial learning impairment caused by the NMDA glutamate antagonist dizocilpine in rats","volume":"741","author":"Burke","year":"2014","journal-title":"Eur. J. Pharmacol."},{"issue":"18","key":"10.1016\/j.neuropharm.2020.108053_bib18","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1007\/s00213-014-3509-2","article-title":"Effects of the nicotinic \u03b17 receptor partial agonist GTS-21 on NMDA-glutamatergic receptor related deficits in sensorimotor gating and recognition memory in rats","volume":"231","author":"Callahan","year":"2014","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2020.108053_bib19","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.neuropharm.2017.02.025","article-title":"Tropisetron sensitizes \u03b17 containing nicotinic receptors to low levels of acetylcholine in vitro and improves memory-related task performance in young and aged animals","volume":"117","author":"Callahan","year":"2017","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.neuropharm.2020.108053_bib20","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1176\/appi.ajp.2016.16030347","article-title":"The RDoC controversy: alternate paradigm or dominant paradigm?","volume":"173","author":"Carpenter","year":"2016","journal-title":"Am. J. Psychiatr."},{"issue":"10","key":"10.1016\/j.neuropharm.2020.108053_bib21","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1523\/JNEUROSCI.19-10-03701.1999","article-title":"Nicotinic acetylcholine receptors containing alpha7 subunits are required for reliable synaptic transmission in situ","volume":"19","author":"Chang","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108053_bib22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ijpsycho.2019.02.005","article-title":"Combining CDP-choline and galantamine, an optimized \u03b17 nicotinic strategy, to ameliorate sensory gating to speech stimuli in schizophrenia","volume":"145","author":"Choueiry","year":"2019","journal-title":"Int. J. Psychophysiol."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.108053_bib23","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1124\/mol.116.104240","article-title":"Understanding the bases of function and modulation of \u03b17 nicotinic receptors: implications for drug discovery","volume":"90","author":"Corradi","year":"2016","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108053_bib24","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3389\/fpsyt.2019.00648","article-title":"The use of cognitive screening in pharmacotherapy trials for cognitive impairment associated with schizophrenia","volume":"10","author":"Cotter","year":"2019","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108053_bib25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jpsychires.2019.03.012","article-title":"Cognitive functioning as a predictor of response to comprehensive cognitive remediation","volume":"113","author":"DeTore","year":"2019","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2020.108053_bib26","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1124\/jpet.108.146514","article-title":"Old and new pharmacology: positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B\/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2- b:4,5-b']di pyrrole-1(2H)-carboxamide)","volume":"328","author":"Dunlop","year":"2009","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108053_bib27","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.bmcl.2013.11.022","volume":"24","author":"Eskildsen","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.neuropharm.2020.108053_bib28","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/bph.13001","article-title":"AQW051, a novel, potent and selective \u03b17 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation","volume":"172","author":"Feuerbach","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108053_bib29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11920-003-0032-2","article-title":"The genetics of sensory gating deficits in schizophrenia","volume":"5","author":"Freedman","year":"2003","journal-title":"Curr. Psychiatr. Rep."},{"issue":"8","key":"10.1016\/j.neuropharm.2020.108053_bib30","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1176\/appi.ajp.2008.07071135","article-title":"Initial phase 2 trial of a nicotinic agonist in schizophrenia","volume":"165","author":"Freedman","year":"2008","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108053_bib31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1146\/annurev-med-092112-142937","article-title":"(2014) \u03b17-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia","volume":"65","author":"Freedman","year":"2014","journal-title":"Annu. Rev. Med."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2020.108053_bib32","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0006-8993(00)02119-3","article-title":"Nicotine reverses GABAergic inhibition of long-term potentiation induction in the hippocampal CA1 region","volume":"863","author":"Fujii","year":"2000","journal-title":"Brain Res."},{"issue":"4","key":"10.1016\/j.neuropharm.2020.108053_bib33","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1177\/0269881117691590","article-title":"First in human trial of a type I positive allosteric modulator of alpha7-nicotinic acetylcholine receptors: pharmacokinetics, safety, and evidence for neurocognitive effect of AVL-3288","volume":"31","author":"Gee","year":"2017","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.108053_bib34","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00001504-200005000-00015","article-title":"Comorbidity of psychiatric and substance abuse disorders","volume":"13","author":"George","year":"2000","journal-title":"Curr. Opin. Psychiatr."},{"issue":"2\u20133","key":"10.1016\/j.neuropharm.2020.108053_bib35","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0920-9964(97)00079-0","article-title":"Glutamate in schizophrenia: clinical and research implications","volume":"27","author":"Goff","year":"1997","journal-title":"Schizophr. Res."},{"issue":"8","key":"10.1016\/j.neuropharm.2020.108053_bib36","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.bcp.2007.05.023","article-title":"Heterogeneity and complexity of native brain nicotinic receptors","volume":"74","author":"Gotti","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108053_bib37","doi-asserted-by":"crossref","first-page":"S353","DOI":"10.1093\/schbul\/sby018.861","article-title":"Exploring participant-level trajectories of cognitive performance among patients with schizophrenia in a multi-national trial","volume":"44","author":"Granger","year":"2018","journal-title":"Schizophr. Bull."},{"issue":"6602","key":"10.1016\/j.neuropharm.2020.108053_bib38","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/383713a0","article-title":"Hippocampal synaptic transmission enhanced by low concentrations of nicotine","volume":"383","author":"Gray","year":"1996","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.neuropharm.2020.108053_bib39","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S0006-3223(00)01027-1","article-title":"Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications","volume":"49","author":"Green","year":"2001","journal-title":"Biol Psychiatry. Feb 15"},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108053_bib40","first-page":"e1","article-title":"Cognition in schizophrenia: past, present, and future","volume":"1","author":"Green","year":"2014","journal-title":"Schizophr Res Cogn. Mar"},{"issue":"8","key":"10.1016\/j.neuropharm.2020.108053_bib41","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1097\/00001756-199906030-00028","article-title":"Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain","volume":"10","author":"Guan","year":"1999","journal-title":"Neuroreport"},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108053_bib42","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00213-011-2258-8","article-title":"Selective nicotinic receptor antagonists: effects on attention and nicotine-induced attentional enhancement","volume":"217","author":"Hahn","year":"2011","journal-title":"Psychopharmacology (Berlin)"},{"issue":"12","key":"10.1016\/j.neuropharm.2020.108053_bib43","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1038\/npp.2016.101","article-title":"The \u03b17 nicotinic agonist ABT-126 in the treatment of cognitive impairment associated with schizophrenia in nonsmokers: results from a randomized controlled phase 2b study","volume":"41","author":"Haig","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.neuropharm.2020.108053_bib44","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1176\/appi.ajp.2015.15010093","article-title":"A randomized trial to assess the efficacy and safety of ABT-126, a selective \u03b17 nicotinic acetylcholine receptor agonist, in the treatment of cognitive impairment in schizophrenia","volume":"173","author":"Haig","year":"2016","journal-title":"Am. J. Psychiatr."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.108053_bib45","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.16m11162","article-title":"Efficacy and safety of the \u03b17-nicotinic acetylcholine receptor agonist ABT-126 in the treatment of cognitive impairment associated with schizophrenia: results from a phase 2b randomized controlled study in smokers","volume":"79","author":"Haig","year":"2018","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108053_bib46","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00213-005-0142-0","article-title":"Tropisetron improves deficient inhibitory auditory processing in DBA\/2 mice: role of alpha 7 nicotinic acetylcholine receptors","volume":"183","author":"Hashimoto","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108053_bib47","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejphar.2006.09.055","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of tropisetron: role of \u03b17 nicotinic receptors","volume":"553","author":"Hashimoto","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108053_bib48","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.bcp.2009.05.030","article-title":"TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia","volume":"78","author":"Hauser","year":"2009","journal-title":"Biochem. Pharmacol."},{"issue":"Pt 3","key":"10.1016\/j.neuropharm.2020.108053_bib49","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1469-7793.1999.769ab.x","article-title":"Synaptic transmission at nicotinic acetylcholine receptors in rat hippocampal organotypic cultures and slices","volume":"515","author":"Hefft","year":"1999","journal-title":"J Physiol."},{"key":"10.1016\/j.neuropharm.2020.108053_bib50","doi-asserted-by":"crossref","first-page":"8352","DOI":"10.1021\/jm400704g","article-title":"Design, synthesis, and activity of a series of arylpyrid-3-ylmethanones as type I positive allosteric modulators of alpha7 nicotinic acetylcholine receptors","volume":"56","author":"Hogenkamp","year":"2013","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.neuropharm.2020.108053_bib51","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00213-013-3275-6","article-title":"Effect of alpha7 nicotinic acetylcholine receptor agonists on attentional set-shifting impairment in rats","volume":"231","author":"Jones","year":"2014","journal-title":"Psychopharmacology (Berlin)"},{"issue":"10","key":"10.1016\/j.neuropharm.2020.108053_bib52","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/jamapsychiatry.2013.155","article-title":"Schizophrenia is a cognitive illness: time for a change in focus","volume":"70","author":"Kahn","year":"2013","journal-title":"JAMA Psychiatr."},{"issue":"10","key":"10.1016\/j.neuropharm.2020.108053_bib53","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1176\/appi.ajp.2019.19080794","article-title":"On the specificity of continuous cognitive decline in schizophrenia","volume":"176","author":"Kahn","year":"2019","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108053_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/s41386-020-0628-9","article-title":"Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients","author":"Kantrowitz","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/j.neuropharm.2020.108053_bib55","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.pnpbp.2003.09.004","article-title":"Half a century of antipsychotics and still a central role for dopamine D2 receptors","volume":"27","author":"Kapur","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry. Oct"},{"issue":"13","key":"10.1016\/j.neuropharm.2020.108053_bib56","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1038\/npp.2015.176","article-title":"Randomized, double-blind, placebo-controlled study of encenicline, an \u03b17 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia","volume":"40","author":"Keefe","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.neuropharm.2020.108053_bib57","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/npp.2017.182","article-title":"Pharmacokinetic limitations on effects of an alpha7-nicotinic receptor agonist in schizophrenia: randomized trial with an extended-release formulation","volume":"43","author":"Kem","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.neuropharm.2020.108053_bib58","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1177\/0269881114553254","article-title":"CDP-choline: effects of the procholine supplement on sensory gating and executive function in healthy volunteers stratified for low, medium and high P50 suppression","volume":"28","author":"Knott","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2020.108053_bib59","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.neulet.2015.02.032","article-title":"Effects of acute CDP-choline treatment on resting state brain oscillations in healthy volunteers","volume":"591","author":"Knott","year":"2015","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2020.108053_bib60","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.pbb.2015.02.004","article-title":"Neurocognitive effects of acute choline supplementation in low, medium and high performer healthy volunteers","volume":"131","author":"Knott","year":"2015","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2020.108053_bib61","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.brainres.2010.07.037","article-title":"Ameliorating effects of tropisetron on dopaminergic disruption of prepulse inhibition via the alpha(7) nicotinic acetylcholine receptor in Wistar rats","volume":"1353","author":"Kohnomi","year":"2010","journal-title":"Brain Res."},{"issue":"5","key":"10.1016\/j.neuropharm.2020.108053_bib62","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0315-18.2018","article-title":"What, if anything, is rodent prefrontal cortex?","volume":"5","author":"Laubach","year":"2018","journal-title":"eNeuro"},{"issue":"3\u20134","key":"10.1016\/j.neuropharm.2020.108053_bib63","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1300\/J374v03n03_05","article-title":"Smoking, genetics and schizophrenia: evidence for self medication","volume":"3","author":"Leonard","year":"2007","journal-title":"J. Dual Diagn."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108053_bib64","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/schbul\/sbm159","article-title":"Methodological issues in current antipsychotic drug trials","volume":"34","author":"Leucht","year":"2008","journal-title":"Schizophr. Bull."},{"issue":"8","key":"10.1016\/j.neuropharm.2020.108053_bib65","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.bcp.2007.07.019","article-title":"Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function","volume":"74","author":"Levin","year":"2007","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.108053_bib66","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00213-013-3126-5","article-title":"High-affinity nicotinic acetylcholine receptor expression and trafficking abnormalities in psychiatric illness","volume":"229","author":"Lewis","year":"2013","journal-title":"Psychopharmacology (Berlin)"},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108053_bib67","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13643-018-0728-3","article-title":"An updated protocol for a systematic review of implementation-related measures","volume":"7","author":"Lewis","year":"2018","journal-title":"Syst. Rev."},{"issue":"6","key":"10.1016\/j.neuropharm.2020.108053_bib68","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/npp.2012.259","article-title":"A randomized exploratory trial of an \u03b1-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia","volume":"38","author":"Lieberman","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"10.1016\/j.neuropharm.2020.108053_bib69","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.euroneuro.2016.07.004","article-title":"Alpha7 nicotinic acetylcholine receptor agonists and PAMs as adjunctive treatment in schizophrenia. An experimental study","volume":"26","author":"Marcus","year":"2016","journal-title":"Eur. Neuropsychopharmacol"},{"issue":"9","key":"10.1016\/j.neuropharm.2020.108053_bib70","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1176\/appi.ajp.2017.17040426","article-title":"Why are innovative drugs failing in phase III?","volume":"174","author":"Marder","year":"2017","journal-title":"Am. J. Psychiatr."},{"issue":"4","key":"10.1016\/j.neuropharm.2020.108053_bib71","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00213-011-2357-6","article-title":"Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914\/SEN34625","volume":"218","author":"Marquis","year":"2011","journal-title":"Psychopharmacology (Berlin)"},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108053_bib72","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00213-003-1750-1","article-title":"Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia","volume":"174","author":"Martin","year":"2004","journal-title":"Psychopharmacology (Berlin)"},{"issue":"5231","key":"10.1016\/j.neuropharm.2020.108053_bib73","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1126\/science.7569895","article-title":"Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors","volume":"269","author":"McGehee","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2020.108053_bib74","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bbr.2015.08.037","article-title":"Nicotinic \u03b17 and \u03b14\u03b22 agonists enhance the formation and retrieval of recognition memory: potential mechanisms for cognitive performance enhancement in neurological and psychiatric disorders","volume":"302","author":"McLean","year":"2016","journal-title":"Behav. Brain Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108053_bib75","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0014-5793(97)00600-5","article-title":"1997 Activation of alpha7 nicotinic acetylcholine receptor promotes survival of spinal cord motoneurons","volume":"411","author":"Messi","year":"1997","journal-title":"FEBS Lett."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2020.108053_bib76","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0006-8993(97)00536-2","article-title":"3-[2,4-Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat alpha7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner","volume":"768","author":"Meyer","year":"1997","journal-title":"Brain Res."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.108053_bib77","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0022-3565(24)37881-4","article-title":"Analysis of 3-(4-hydroxy, 2-Methoxybenzylidene)anabaseine selectivity and activity at human and rat alpha-7 nicotinic receptors","volume":"287","author":"Meyer","year":"1998","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"2\u20133","key":"10.1016\/j.neuropharm.2020.108053_bib78","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.schres.2004.02.001","article-title":"N-acetyl-aspartate levels in the dorsolateral prefrontal cortex in the early years of schizophrenia are inversely related to disease duration","volume":"73","author":"Molina","year":"2005","journal-title":"Schizophr. Res."},{"issue":"7","key":"10.1016\/j.neuropharm.2020.108053_bib79","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.biopsych.2018.02.010","article-title":"Meeting report: can we make animal models of human mental illness?","volume":"84","author":"Monteggia","year":"2018","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108053_bib80","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pscychresns.2006.09.004","article-title":"Progressive changes of white matter integrity in schizophrenia revealed by diffusion tensor imaging","volume":"154","author":"Mori","year":"2007","journal-title":"Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108053_bib81","doi-asserted-by":"crossref","first-page":"29","DOI":"10.31887\/DCNS.2012.14.1\/smorris","article-title":"Research Domain Criteria: cognitive systems, neural circuits, and dimensions of behavior","volume":"14","author":"Morris","year":"2012","journal-title":"Dialogues Clin. Neurosci."},{"issue":"4","key":"10.1016\/j.neuropharm.2020.108053_bib82","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/2045125317752915","article-title":"The antipsychotic landscape: dopamine and beyond","volume":"8","author":"Morrison","year":"2018","journal-title":"Ther Adv Psychopharmacol"},{"issue":"10","key":"10.1016\/j.neuropharm.2020.108053_bib83","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/nn.2647","article-title":"Animal models of neuropsychiatric disorders","volume":"13","author":"Nestler","year":"2010","journal-title":"Nat. Neurosci."},{"issue":"19","key":"10.1016\/j.neuropharm.2020.108053_bib84","doi-asserted-by":"crossref","first-page":"8059","DOI":"10.1073\/pnas.0701321104","article-title":"Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators","volume":"104","author":"Ng","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.neuropharm.2020.108053_bib85","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.euroneuro.2015.04.018","article-title":"Positive allosteric modulation of alpha 7 nicotinic acetylcholine receptors enhances recognition memory and cognitive flexibility in rats","volume":"25","author":"Nikiforuk","year":"2015","journal-title":"Eur. Neuropsychopharmacol"},{"issue":"4","key":"10.1016\/j.neuropharm.2020.108053_bib86","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00213-013-3064-2","article-title":"A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia","volume":"228","author":"Noroozian","year":"2013","journal-title":"Psychopharmacology (Berlin)"},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108053_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0006-3223(96)00302-2","article-title":"Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers","volume":"42","author":"Olincy","year":"1997","journal-title":"Biol. Psychiatr."},{"issue":"6","key":"10.1016\/j.neuropharm.2020.108053_bib88","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1001\/archpsyc.63.6.630","article-title":"Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia","volume":"63","author":"Olincy","year":"2006","journal-title":"Arch. Gen. Psychiatr."},{"issue":"6","key":"10.1016\/j.neuropharm.2020.108053_bib89","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/npp.2017.292","article-title":"Initial cross-over test of A positive allosteric modulator of alpha-7 nicotinic receptors to aid cessation in smokers with or without schizophrenia","volume":"43","author":"Perkins","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108053_bib90","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.npp.1301188","article-title":"A novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia","volume":"32","author":"Pichat","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108053_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2017.04.024","article-title":"Effects of BMS-902483, an \u03b17 nicotinic acetylcholine receptor partial agonist, on cognition and sensory gating in relation to receptor occupancy in rodents","volume":"807","author":"Pieschl","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108053_bib92","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0091-3057(96)00516-3","article-title":"Different effects of tropisetron and ondansetron in learning and memory paradigms","volume":"56","author":"Pitsikas","year":"1997","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2020.108053_bib93","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.bcp.2017.11.017","article-title":"Tropisetron enhances recognition memory in rats chronically treated with risperidone or quetiapine","volume":"151","author":"Poddar","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108053_bib94","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.neuropharm.2016.10.002","article-title":"3-Furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the \u03b17 nicotinic receptor, reverses schizophrenia-like cognitive and social deficits in rats","volume":"113","author":"Potasiewicz","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108053_bib95","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.neuropharm.2011.10.024","article-title":"EVP-6124, a novel and selective alpha7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of alpha7 nicotinic acetylcholine receptors","volume":"62","author":"Prickaerts","year":"2012","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.neuropharm.2020.108053_bib96","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/neu.10109","article-title":"Desensitization of neuronal nicotinic receptors","volume":"53","author":"Quick","year":"2002","journal-title":"J. Neurobiol."},{"key":"10.1016\/j.neuropharm.2020.108053_bib97","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1192\/bjp.bp.105.013276","article-title":"Premorbid functioning and treatment response in recent-onset schizophrenia","volume":"189","author":"Rabinowitz","year":"2006","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2020.108053_bib98","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1124\/jpet.112.197970","article-title":"Effects of the novel alpha7 nicotinic acetylcholine receptor agonist ABT-107 on sensory gating in DBA\/2 mice: pharmacodynamic characterization","volume":"343","author":"Radek","year":"2012","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108053_bib99","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1124\/jpet.108.150094","article-title":"Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders","volume":"329","author":"Roncarati","year":"2009","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"4","key":"10.1016\/j.neuropharm.2020.108053_bib100","first-page":"218","article-title":"Research domain Criteria: strengths, weaknesses, and potential alternatives for future psychiatric research","volume":"5","author":"Ross","year":"2019","journal-title":"Mol Neuropsychiatry"},{"key":"10.1016\/j.neuropharm.2020.108053_bib101","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1744-859X-9-27","article-title":"A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia","volume":"9","author":"Shiina","year":"2010","journal-title":"Ann. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108053_bib102","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.brainres.2015.02.044","article-title":"Maximizing the effect of an \u03b17 nicotinic receptor PAM in a mouse model of schizophrenia-like sensory inhibition deficits","volume":"1611","author":"Stevens","year":"2015","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108053_bib103","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.eurpsy.2004.09.005","article-title":"Tobacco use in schizophrenia: a study of cotinine concentrations in the saliva of patients and controls","volume":"20","author":"Strand","year":"2005","journal-title":"Eur Psychiatry. Jan"},{"issue":"3","key":"10.1016\/j.neuropharm.2020.108053_bib104","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/ntr\/nty166","article-title":"Nicotinic acetylcholine receptor ligands, cognitive function, and preclinical approaches to drug discovery","volume":"21","author":"Terry","year":"2019","journal-title":"Nicotine Tob. Res."},{"key":"10.1016\/j.neuropharm.2020.108053_bib105","first-page":"65","article-title":"Preclinical characterization of A-582941: a novel \u03b17 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties","volume":"14","author":"Tietje","year":"2008","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.neuropharm.2020.108053_bib106","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1124\/jpet.107.120436","article-title":"An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo","volume":"323","author":"Timmermann","year":"2007","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.108053_bib107","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/ntr\/nty034","article-title":"Alpha7 nicotinic receptors as therapeutic targets in schizophrenia","volume":"21","author":"Tregellas","year":"2019","journal-title":"Nicotine Tob. Res."},{"issue":"7","key":"10.1016\/j.neuropharm.2020.108053_bib108","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/npp.2014.17","article-title":"A randomized, placebo-controlled study investigating the nicotinic \u03b17 agonist, RG3487, for cognitive deficits in schizophrenia","volume":"39","author":"Umbricht","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.neuropharm.2020.108053_bib109","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/npp.2011.306","article-title":"Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review","volume":"37","author":"Undurraga","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108053_bib110","doi-asserted-by":"crossref","first-page":"109338","DOI":"10.1016\/j.cellsig.2019.06.003","article-title":"Antagonizing \u03b17 nicotinic receptors with methyllycaconitine (MLA) potentiates receptor activity and memory acquisition","volume":"62","author":"van Goethem","year":"2019","journal-title":"Cell. Signal."},{"key":"10.1016\/j.neuropharm.2020.108053_bib111","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1124\/jpet.110.171892","article-title":"RG3487, a novel nicotinic alpha7 receptor partial agonist, improves cognition and sensorimotor gating in rodents","volume":"336","author":"Wallace","year":"2011","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108053_bib112","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.neuropharm.2012.06.040","article-title":"Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study","volume":"64","author":"Winterer","year":"2013","journal-title":"Neuropharmacology"},{"issue":"14","key":"10.1016\/j.neuropharm.2020.108053_bib113","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.2174\/1381612822666160127113912","article-title":"Targeting functional biomarkers in schizophrenia with neuroimaging","volume":"22","author":"Wylie","year":"2016","journal-title":"Curr. Pharmaceut. Des."},{"issue":"29","key":"10.1016\/j.neuropharm.2020.108053_bib114","doi-asserted-by":"crossref","first-page":"12078","DOI":"10.1073\/pnas.1307849110","article-title":"Nicotinic \u03b17 receptors enhance NMDA cognitive circuits in dorsolateral prefrontal cortex","volume":"110","author":"Yang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2020.108053_bib115","doi-asserted-by":"crossref","first-page":"39941","DOI":"10.1038\/srep39941","article-title":"Chrna7 deficient mice manifest no consistent neuropsychiatric and behavioral phenotypes","volume":"7","author":"Yin","year":"2017","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.neuropharm.2020.108053_bib116","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.bcp.2013.06.031","article-title":"Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia","volume":"86","author":"Young","year":"2013","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"10.1016\/j.neuropharm.2020.108053_bib117","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1176\/appi.ajp.2012.11081289","article-title":"Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia","volume":"169","author":"Zhang","year":"2012","journal-title":"Am. J. Psychiatr."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820301192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820301192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:01:22Z","timestamp":1758438082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390820301192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":117,"alternative-id":["S0028390820301192"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108053","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u03b17 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: Update on animal and clinical studies and strategies for the future","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108053"}}